Clinical trials: Histological Response
Chronic Myelogenous Leukemia
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia…
- Trial name
- NCT01274351
- Testing
- Nilotinib
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
Preoperative Immune checkpoint inhibitors combined with chemotherapy have revolutionized the treatment landscape of locally advanced esophageal squamous cell carcinoma.
- Conditions
- Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy
- Trial name
- PICCRT (NCT05596890)
- Testing
- Paclitaxel-albumin, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Provincial People's Hospital
Melanoma (Skin)
S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898183
- Testing
- gene expression analysis, polymorphism analysis
- Volunteers
- 91 people
- Sponsor
- SWOG Cancer Research Network
Hematological Malignancies
Tissue Microarray of Hematological Malignancies
The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative…
- Trial name
- HemaTMA (NCT04142372)
- Where
- Finland
- Volunteers
- 5,000 people
- Sponsor
- Tampere University Hospital
Glioblastoma, Glioblastoma, IDH-wildtype
Biomolecular Analysis for Predicting Response to Regorafenib
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
- Trial name
- RegoRec (NCT05759195)
- Testing
- Biomolecular tumor analysis
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Multiple Myeloma
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had…
- Trial name
- NCT05354557
- Testing
- Iberdomide
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Quality of Life
Quality of Life in Patients With Multiple Myeloma
The purpose of this study is to determine Clinically important difference and Response shift in quality of life in patients with Multiple Myeloma.
- Trial name
- NCT00290095
- Where
- Norway
- Volunteers
- 260 people
- Sponsor
- Ullevaal University Hospital
Malignancy, Cancer
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
This is a prospective interventional study designed to investigate the effect of Immune Reconstitution clinic visits and pneumococcal vaccination (PCV-21) on infection risk, anti-infective prophylaxis adherence, and vaccine…
- Conditions
- Malignancy, Cancer, Hematological Malignancies, Lymphoma
- Trial name
- NCT07071909
- Testing
- Commercial CAR-T, Investigational CAR-T
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01940809
- Testing
- Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myeloid Leukemia
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care.
- Conditions
- Acute Myeloid Leukemia, Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT05035706
- Testing
- Biopsy, Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukaemia
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
The purpose of this study is to investigate whether some patients with excellent responses to chronic myeloid leukaemia (CML) treatment are being overtreated, and can remain well on either a lower dose of treatment or without…
- Trial name
- DESTINY (NCT01804985)
- Testing
- Imatinib, nilotinib, dasatinib
- Where
- United Kingdom
- Volunteers
- 174 people
- Sponsor
- University of Liverpool
Renal Cell Carcinoma
Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma
Magnetic Resonance Imaging (MRI) including Arterial Spin Labeling (ASL) will be performed before, during, and after the treatment, in a total of up to 6 MRI sessions until 7 months after the first session, or when progression is…
- Trial name
- NCT04831138
- Testing
- MRI with ASL, ASL-MRI
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Missing Several Teeth, Minimum of 2 Dental Implants Needed
Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers.
Baseline: Standard preparation of the osteotomy Placement of 2 dental implants On each implant one of both types of healing abutments is placed Suturing Standardized radiography to measure bone-levels at baseline Digital…
- Trial name
- STRANDI (NCT01620918)
- Testing
- normal healing abutment, nano-structured healing abutment
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Ghent
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
- Conditions
- Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- NCT05358938
- Testing
- Exercise, Checkpoint Blockade, Immune
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Myeloma Treatment in Real Life
As part of an oral treatment regimen in ambulatory practice, certain uses in connection with drug consumption associated could alter treatment outcomes observed in randomized clinical trials.
- Trial name
- NCT03638232
- Testing
- Administrative data, Medical data, Drug exposition data
- Volunteers
- 236 people
- Sponsor
- University Hospital, Toulouse
Multiple Myeloma, Myeloma, Multiple
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
This study will collect blood samples from healthy volunteers and volunteers with multiple myeloma who are going to get the seasonal flu, pneumonia, haemophilus influenzae B (HIB), and/or meningococcus vaccines.
- Conditions
- Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
- Trial name
- NCT02294487
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia
PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia
The purpose of this study is to evaluate the predictive value of 18F-FDG PET probe signal in de novo diagnosed or refractory/relapsed patients with acute myeloid leukemia.
- Trial name
- FDG-PETAML (NCT05919199)
- Testing
- No intervention
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Jinan University
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
This phase II trial studies the side effects and how well Akt inhibitor MK2206 (MK2206) and erlotinib hydrochloride works in treating patients with advanced non-small cell lung cancer who have progressed after previous response…
- Conditions
- Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma
- Trial name
- NCT01294306
- Testing
- Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cavity Cancer
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: DNA analysis of tumor tissue from patients with cancer may help doctors predict how patients respond to treatment and plan the best treatment.
- Trial name
- NCT00897806
- Testing
- Microarray analysis, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)
this multi-center prospective cohort study is to evaluate the efficacy and the safety of drug-eluting bead TACE compared with conventional TACE in terms of objective response in unresectable HCC
- Trial name
- NCT03969576
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Air Force Military Medical University, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.